Clinical Trial Update: A Study to Investigate the Safety and Pharmacodynamics of Repeat Intranasal Administration of the TLR7 Agonist GSK2245035 in Subjects With Respiratory Allergies [Phase 2]

View source ↗

Summary

A phase 2 study evaluating the safety and pharmacodynamics of repeat intranasal dosing of the TLR7 agonist GSK2245035 in subjects with asthma and allergic rhini…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Asthma

Drugs mentioned

• GSK2245035 (GSK2245035)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma and Rhinitis | Phase 2 | Status: COMPLETED